首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1279742

2022-2029年全球肉瘤藥物市場規模研究和預測，按治療類型（化療、靶向治療）和區域分析

Global Sarcoma Drugs Market Size study & Forecast, by Treatment Type (Chemotherapy, Targeted Therapy) and Regional Analysis, 2022-2029

出版日期: 2023年05月13日 | 出版商:

Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

肉瘤是一種可以出現在身體任何部位的癌症。肉瘤，也被稱為軟組織肉瘤，是一大類在骨骼和軟組織中發展的腫瘤。軟組織肉瘤形成於連接、包裹和支持其他身體結構的組織。肌肉、脂肪、血管、神經、肌腱和關節襯裡構成了這個框架。有超過70種不同類型的肉瘤。肉瘤的治療方式將取決於其類型、位置和其他因素。惡性骨腫瘤和軟組織肉瘤是可以使用肉瘤藥物的兩種情況。軟組織肉瘤包括橫紋肌肉瘤、滑膜細胞肉瘤、白肌肉瘤和皮纖維肉瘤。化療、靶向藥物治療和其他程序是肉瘤治療的一部分。推動市場增長的關鍵因素是軟組織肉瘤患病率的上升，新的肉瘤藥物的產品批准數量增加，以及主要市場參與者擴大採用關鍵戰略，如收購、合作、協議和夥伴關係，預計將支持預測期間的市場增長。

此外，軟組織肉瘤發病率的上升預計將為肉瘤藥物市場創造有利可圖的需求。例如，美國癌症協會估計，全國將發現12,750個軟組織肉瘤的新病例，其中7,240個是男性，5,510個是女性。根據該協會對死亡率的估計，預計2019年將有5270名美國人死於肉瘤。據報導，在美國，每年100萬人口中約有40人患有肉瘤。此外，對肉瘤藥物的研究和開發的投資不斷增加，預計在預測期內將為市場創造有利可圖的機會。然而，在2022-2029年的預測期內，肉瘤藥物的高成本扼殺了市場的增長。

全球肉瘤藥物市場研究涵蓋的主要地區包括亞太、北美、歐洲、拉美和世界其他地區。由於主要市場參與者的存在，研究活動數量的增加，醫療部門的技術進步和該地區軟組織肉瘤患病率的增加，北美是全球市場佔有率的主導地區。而亞太地區在預測期內也將表現出最高的增長率，這是因為政府組織增加支出以發展醫療保健部門，癌症患病率的上升和肉瘤藥物行業數量的增長等因素將為整個亞太地區的肉瘤藥物市場創造有利的增長前景。

該研究的目的是確定近年來不同領域和國家的市場規模，並對未來幾年的價值進行預測。該報告旨在將研究涉及的國家內的行業的品質和數量方面都涵蓋其中。

該報告還提供了關於關鍵方面的詳細資訊，如驅動因素和挑戰，這將確定市場的未來增長。此外，它還涵蓋了微觀市場的潛在機會，供利益相關者投資，並詳細分析了競爭格局和主要參與者的產品。 .

波特五力模型
- 供應商的議價能力
- 買方的議價能力
- 新進入者的威脅
- 替代品的威脅
- 競爭性的競爭
波特五力模型的未來方法（2019-2029年）
PEST分析
- 政治因素
- 經濟
- 社會
- 技術
最佳投資機會
最佳策略
行業專家展望
分析師建議和結論

第五章：風險評估：COVID-19的影響

評估COVID-19對行業的整體影響
COVID-19前和COVID-19後的市場情況

第六章：全球肉瘤藥物市場，按治療類型分類

市場簡介
按治療類型分類的全球肉瘤藥物市場，性能-潛力分析
2019-2029年全球肉瘤藥物市場按治療類型的估計和預測
肉瘤藥物市場，次級細項分析
- 化療
- 靶向治療

第七章：全球肉瘤藥物市場，區域分析

肉瘤藥物市場，區域市場簡介
北美洲
- 美國
  - 2019-2029年，治療類型細分估計和預測
- 加拿大
歐洲肉瘤藥物市場簡介
- 英國
- 德國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區肉瘤藥物市場簡介
- 中國
- 中國
- 日本
- 澳大利亞
- 韓國
- 亞太其他地區
拉丁美洲肉瘤藥物市場簡況
- 巴西
- 墨西哥
- 拉丁美洲其他地區
世界其他地區

第八章：競爭情報

頂級市場戰略
公司簡介
- Baxter Healthcare Corporation
  - 關鍵資訊
  - 概況
  - 財務（取決於數據的可用性）
  - 產品摘要
  - 近期發展情況
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- AgonOX, Inc.
- Eisai Co., Ltd.
- GlaxoSmithKline, plc.
- Hoffmann-La Roche AG.
- Johnson and Johnson
- MERCK & CO., Inc
- Novartis AG

第九章：研究過程

研究過程
- 資料探勘
- 分析
- 市場評估
- 驗證
- 出版
研究屬性
研究假設

簡介目錄圖表

Global Sarcoma Drugs Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Sarcoma is a type of cancer that can appear anywhere on the body. Sarcomas, also referred to as soft tissue sarcomas, are a broad category of tumors that develop in the bones and soft tissues. Soft tissue sarcomas form in the tissues that connect, envelop, and support other body structures. The muscle, fat, blood vessels, nerves, tendons, and joint lining make up this framework. There are more than 70 different types of sarcoma. The way that the sarcoma is treated will depend on the type, location, and other factors. Malignant bone tumours and soft tissue sarcoma are two conditions for which sarcoma drugs can be used. Soft tissue sarcomas include rhabdomyosarcoma, synovial cell sarcoma, leiomyosarcoma, and dermatofibrosarcoma. Chemotherapy, targeted medication therapy, and other procedures are part of the sarcoma treatment. The key factor driving the market growth is rise in the prevalence of soft tissue sarcoma, increasing number of product approval for new sarcoma drugs, and growing adoption of key strategies such as acquisition, collaboration, agreement and partnership by key market players that anticipated to support the market growth during forecast period.

Moreover, the rising prevalence of soft tissue sarcoma is anticipated to create the lucrative demand for the sarcoma drugs market. For instance, The American Cancer Society estimates that 12,750 new cases of soft tissue sarcoma will be identified across the country, 7,240 of which will be male and 5,510 of which will be female. According to this society's estimates of mortality, 5,270 Americans are predicted to die by sarcoma in 2019. It has been reported that about 40 people in 1 million have Sarcoma in the United States yearly. Additionally, rising investment for the research and development of sarcoma drugs is anticipated to create the lucrative opportunity for the market during forecast period. However, the high cost of Sarcoma Drugs stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Sarcoma Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key market players, rising the number of research activities, growing technological advancement in the healthcare sector and increasing the prevalence of soft tissue sarcoma in the region. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as increase in expenditure by government organization to develop healthcare sector, rise in prevalence of cancer and growing the number of sarcoma drugs industry would create lucrative growth prospects for the Sarcoma Drugs market across Asia Pacific region.

Major market players included in this report are:

Baxter Healthcare Corporation
Bristol-Myers Squibb Company
Daiichi Sankyo Company Limited
AgonOX, Inc.
Eisai Co., Ltd.
GlaxoSmithKline, plc.
Hoffmann-La Roche AG.
Johnson and Johnson
MERCK & CO., Inc
Novartis AG

Recent Developments in the Market:

In 2020, Junshi Biosciences, a worldwide biopharmaceutical company, acquired FDA approval for Orphan Drug name for toripalimab to treat soft tissue sarcoma. This approval is anticipated to help the company offer innovative products and bring in new clients, boosting revenue.

Global Sarcoma Drugs Market Report Scope:

Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered: Treatment Type, Region
Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Treatment Type:

Chemotherapy
Targeted Therapy

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Chapter 1. Executive Summary

1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
- 1.2.1. Sarcoma Drugs Market, by Region, 2019-2029 (USD Billion)
- 1.2.2. Sarcoma Drugs Market, by Treatment Type, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption

Chapter 2. Global Sarcoma Drugs Market Definition and Scope

2.1. Objective of the Study
2.2. Market Definition & Scope
- 2.2.1. Scope of the Study
- 2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates

Chapter 3. Global Sarcoma Drugs Market Dynamics

3.1. Sarcoma Drugs Market Impact Analysis (2019-2029)
- 3.1.1. Market Drivers
  - 3.1.1.1. Rise in the prevalence of soft tissue sarcoma
  - 3.1.1.2. Increasing number of product approval for new sarcoma drugs
- 3.1.2. Market Challenges
  - 3.1.2.1. High Cost of Sarcoma Drugs
- 3.1.3. Market Opportunities
  - 3.1.3.1. Rising investment for the research and development of sarcoma drugs

Chapter 4. Global Sarcoma Drugs Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Sarcoma Drugs Market, by Treatment Type

6.1. Market Snapshot
6.2. Global Sarcoma Drugs Market by Treatment Type, Performance - Potential Analysis
6.3. Global Sarcoma Drugs Market Estimates & Forecasts by Treatment Type 2019-2029 (USD Billion)
6.4. Sarcoma Drugs Market, Sub Segment Analysis
- 6.4.1. Chemotherapy
- 6.4.2. Targeted Therapy

Chapter 7. Global Sarcoma Drugs Market, Regional Analysis

7.1. Sarcoma Drugs Market, Regional Market Snapshot
7.2. North America Sarcoma Drugs Market
- 7.2.1. U.S. Sarcoma Drugs Market
  - 7.2.1.1. Treatment Type breakdown estimates & forecasts, 2019-2029
- 7.2.2. Canada Sarcoma Drugs Market
7.3. Europe Sarcoma Drugs Market Snapshot
- 7.3.1. U.K. Sarcoma Drugs Market
- 7.3.2. Germany Sarcoma Drugs Market
- 7.3.3. France Sarcoma Drugs Market
- 7.3.4. Spain Sarcoma Drugs Market
- 7.3.5. Italy Sarcoma Drugs Market
- 7.3.6. Rest of Europe Sarcoma Drugs Market
7.4. Asia-Pacific Sarcoma Drugs Market Snapshot
- 7.4.1. China Sarcoma Drugs Market
- 7.4.2. India Sarcoma Drugs Market
- 7.4.3. Japan Sarcoma Drugs Market
- 7.4.4. Australia Sarcoma Drugs Market
- 7.4.5. South Korea Sarcoma Drugs Market
- 7.4.6. Rest of Asia Pacific Sarcoma Drugs Market
7.5. Latin America Sarcoma Drugs Market Snapshot
- 7.5.1. Brazil Sarcoma Drugs Market
- 7.5.2. Mexico Sarcoma Drugs Market
- 7.5.3. Rest of Latin America Sarcoma Drugs Market
7.6. Rest of The World Sarcoma Drugs Market

Chapter 8. Competitive Intelligence

8.1. Top Market Strategies
8.2. Company Profiles
- 8.2.1. Baxter Healthcare Corporation
  - 8.2.1.1. Key Information
  - 8.2.1.2. Overview
  - 8.2.1.3. Financial (Subject to Data Availability)
  - 8.2.1.4. Product Summary
  - 8.2.1.5. Recent Developments
- 8.2.2. Bristol-Myers Squibb Company
- 8.2.3. Daiichi Sankyo Company Limited
- 8.2.4. AgonOX, Inc.
- 8.2.5. Eisai Co., Ltd.
- 8.2.6. GlaxoSmithKline, plc.
- 8.2.7. Hoffmann-La Roche AG.
- 8.2.8. Johnson and Johnson
- 8.2.9. MERCK & CO., Inc
- 8.2.10. Novartis AG

Chapter 9. Research Process

9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption

簡介目錄圖表

LIST OF TABLES

TABLE 1. Global Sarcoma Drugs Market, report scope
TABLE 2. Global Sarcoma Drugs Market estimates & forecasts by Region 2019-2029 (USD Billion)
TABLE 3. Global Sarcoma Drugs Market estimates & forecasts by Treatment Type 2019-2029 (USD Billion)
TABLE 4. Global Sarcoma Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 5. Global Sarcoma Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 6. Global Sarcoma Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 7. Global Sarcoma Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 8. Global Sarcoma Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 9. Global Sarcoma Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 10. Global Sarcoma Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 11. Global Sarcoma Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 12. Global Sarcoma Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 13. Global Sarcoma Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 14. U.S. Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 15. U.S. Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 16. U.S. Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 17. Canada Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 18. Canada Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 19. Canada Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 20. UK Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 21. UK Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 22. UK Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 23. Germany Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 24. Germany Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 25. Germany Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 26. France Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 27. France Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 28. France Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 29. Italy Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 30. Italy Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 31. Italy Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 32. Spain Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 33. Spain Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 34. Spain Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 35. RoE Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 36. RoE Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 37. RoE Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 38. China Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 39. China Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 40. China Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 41. India Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 42. India Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 43. India Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 44. Japan Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 45. Japan Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 46. Japan Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 47. South Korea Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 48. South Korea Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 49. South Korea Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 50. Australia Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 51. Australia Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 52. Australia Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 53. RoAPAC Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 54. RoAPAC Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 55. RoAPAC Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 56. Brazil Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 57. Brazil Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 58. Brazil Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 59. Mexico Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 60. Mexico Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 61. Mexico Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 62. RoLA Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 63. RoLA Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 64. RoLA Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 65. Row Sarcoma Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 66. Row Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 67. Row Sarcoma Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 68. List of secondary sources, used in the study of global Sarcoma Drugs Market
TABLE 69. List of primary sources, used in the study of global Sarcoma Drugs Market
TABLE 70. Years considered for the study
TABLE 71. Exchange rates considered